Skip to main content
Annolyse
Back to companies

RAD · NZX

Radius Residential Care (RAD)

Healthcare / Aged careCovered: FY23 - FY267 published briefings

Radius Residential Care is an NZX-listed healthcare / aged care company. Its latest covered result is FY26, with FY23 - FY26 of source-backed result history on Annolyse.

Sections

Latest result

Latest metrics

FY26, released 13 May 2026

← Swipe to view more
RAD latest metrics
MetricValueChange
Revenue$200.1m↑ +14.2%
EBITDA$27.4m↑ +16.6%
NPAT$9.5m↑ +35.7%
Operating cash flow$25.1m↑ +25.3%
OCF / EBITDA %91.8%Outside range high ocf / ebitda cash conversion. 91.8%; 3-period range 28.4% to 85.5%. OCF / EBITDA cash conversion: 91.8%, above normal range; 3-period mean 60.4%, range 28.4%-85.5%.↑ +6.4pp
Net debt$68.7m↑ +1.5%
Net debt / EBITDA2.51xOutside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x.↓ -13.1%
ROE %12.4%Outside range high roe. 12.4%; 3-period range -13.2% to 10.6%. ROE: 12.4%, above normal range; 3-period mean -1.8%, range -13.2%-10.6%.↑ +1.8pp
DPS1.2c↑ +50.0%
Payout ratio vs NPAT %66.1%↑ +10.3pp

Source: latest published briefing (FY26, released 13 May 2026). Change compares against the prior equivalent period: FY25, released 21 May 2025.

Valuation

Valuation

Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.

Prices as at close, 18 September 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$120.5m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

12.68x

i

Recent market cap compared with trailing earnings.

EPS

0.03

i

Recent filing-derived earnings per share.

PEG

0.36x

i

P/E compared with recent earnings growth.

EV/EBITDA

6.91x

i

Enterprise value compared with recent EBITDA.

P/FCF

13.31x

i

Market cap compared with recent free cash flow.

P/B

1.58x

i

Market value compared with latest reported equity.

Income and investment-company measures

Yield and investment-company valuation where supported.

Dividend yield

5.2%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Price history

Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.

Share price

Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.

Loading chart...

P/E over time

Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.

Loading chart...

Ask about RAD

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask company questions.

What changed in the latest result?What is unusual in the historical context?How has cash conversion changed over time?Compare this company with CNU.

Checking account...

Financial history

Performance over time

The latest period is shown first.

← Swipe to view more
RAD metric history
MetricFY2612 MONTHS13 May 2026HY266 MONTHS19 November 2025FY2512 MONTHS21 May 2025HY256 MONTHS25 November 2024FY2412 MONTHS29 May 2024HY246 MONTHS27 November 2023FY2312 MONTHS29 May 2023Trend
Revenue$200.1m$100.2m$175.3m$85.4m$168.7m$83.3m$146.3m
Chart
Revenue growth %14.2%19.0%3.9%Outside range low revenue growth. 3.9%; 3-period range 10.8% to 15.4%. Revenue growth: 3.9%, below normal range; 3-period mean 13.5%, range 10.8%-15.4%.2.5%15.4%Outside range high revenue growth. 15.4%; 3-period range 3.9% to 14.2%. Revenue growth: 15.4%, above normal range; 3-period mean 9.6%, range 3.9%-14.2%.19.2%10.8%
Chart
  • FY24 Revenue growth %: Outside range high revenue growth. 15.4%; 3-period range 3.9% to 14.2%. Revenue growth: 15.4%, above normal range; 3-period mean 9.6%, range 3.9%-14.2%.
  • FY25 Revenue growth %: Outside range low revenue growth. 3.9%; 3-period range 10.8% to 15.4%. Revenue growth: 3.9%, below normal range; 3-period mean 13.5%, range 10.8%-15.4%.
EBITDA$27.4m$14.9m$23.5m$9.6m$20.9m$10.5m$14.2m
Chart
EBITDA margin %13.7%Outside range high ebitda margin. 13.7%; 3-period range 9.7% to 13.4%. EBITDA margin: 13.7%, above normal range; 3-period mean 11.8%, range 9.7%-13.4%.14.9%13.4%11.3%12.4%12.5%9.7%Outside range low ebitda margin. 9.7%; 3-period range 12.4% to 13.7%. EBITDA margin: 9.7%, below normal range; 3-period mean 13.2%, range 12.4%-13.7%.
Chart
  • FY26 EBITDA margin %: Outside range high ebitda margin. 13.7%; 3-period range 9.7% to 13.4%. EBITDA margin: 13.7%, above normal range; 3-period mean 11.8%, range 9.7%-13.4%.
PBT$14.3m$8.5m$10.5m$2.8m$3.6m$1.6m-$3m
Chart
PBT growth %36.2%203.6%191.7%75.0%—-27.3%—
Chart
NPAT$9.5m$6.3m$7m$2m-$8.5m$1.4m-$2.1m
Chart
NPAT growth %35.7%215.0%—42.9%—-17.6%—
Chart
Operating cash flow$25.1m$13.3m$20.1m$6.6m$14.1m$5.6m$4m
Chart
OCF / EBITDA %91.8%Outside range high ocf / ebitda cash conversion. 91.8%; 3-period range 28.4% to 85.5%. OCF / EBITDA cash conversion: 91.8%, above normal range; 3-period mean 60.4%, range 28.4%-85.5%.89.3%85.4%68.5%67.4%53.6%28.4%Outside range low ocf / ebitda cash conversion. 28.4%; 3-period range 67.4% to 91.8%. OCF / EBITDA cash conversion: 28.4%, below normal range; 3-period mean 81.5%, range 67.4%-91.8%.
Chart
  • FY26 OCF / EBITDA %: Outside range high ocf / ebitda cash conversion. 91.8%; 3-period range 28.4% to 85.5%. OCF / EBITDA cash conversion: 91.8%, above normal range; 3-period mean 60.4%, range 28.4%-85.5%.
FCF pre-lease$9m$9.6m$13.7m$3.7m$10.6m$3.7m-$54.6m
Chart
DPS1.2c1.0c0.8c0.7c0.7c——
Chart
Payout ratio vs NPAT %66.1%44.8%55.8%94.2%———
Chart
Annual payout ratio vs EPS %66.1%—55.8%————
Chart
ROE %12.4%Outside range high roe. 12.4%; 3-period range -13.2% to 10.6%. ROE: 12.4%, above normal range; 3-period mean -1.8%, range -13.2%-10.6%.9.0%10.6%3.1%-13.2%Outside range low roe. -13.2%; 3-period range -2.9% to 12.4%. ROE: -13.2%, below normal range; 3-period mean 6.7%, range -2.9%-12.4%.1.9%-2.9%
Chart
  • FY24 ROE %: Outside range low roe. -13.2%; 3-period range -2.9% to 12.4%. ROE: -13.2%, below normal range; 3-period mean 6.7%, range -2.9%-12.4%.
  • FY26 ROE %: Outside range high roe. 12.4%; 3-period range -13.2% to 10.6%. ROE: 12.4%, above normal range; 3-period mean -1.8%, range -13.2%-10.6%.
Net debt$68.7m$63.7m$67.7m$73.2m$73.5m$96.8m$100.1m
Chart
Net debt / EBITDA2.51xOutside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x.4.27x2.89x7.59x3.51x9.26x7.05xOutside range high net debt / ebitda. 7x; 3-period range 2.51x to 3.5x. Net debt / EBITDA: 7.00x, above normal range; 3-period mean 2.97x, range 2.51x-3.50x.
Chart
  • FY26 Net debt / EBITDA: Outside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x.
Debtor days21Outside range low debtor days. 21d; 3-period range 24d to 33d. Debtor days: 21.2 days, below normal range; 3-period mean 27.4 days, range 24.0 days-32.6 days.232426263033Outside range high debtor days. 33d; 3-period range 21d to 26d. Debtor days: 32.6 days, above normal range; 3-period mean 23.6 days, range 21.2 days-25.6 days.
Chart
  • FY26 Debtor days: Outside range low debtor days. 21d; 3-period range 24d to 33d. Debtor days: 21.2 days, below normal range; 3-period mean 27.4 days, range 24.0 days-32.6 days.
Inventory days1Outside range low inventory days. 1d; 3-period range 1d to 2d. Inventory days: 1.1 days, below normal range; 3-period mean 1.4 days, range 1.2 days-1.9 days.111122Outside range high inventory days. 2d; 3-period range 1d to 1d. Inventory days: 1.9 days, above normal range; 3-period mean 1.2 days, range 1.1 days-1.2 days.
Chart
  • FY26 Inventory days: Outside range low inventory days. 1d; 3-period range 1d to 2d. Inventory days: 1.1 days, below normal range; 3-period mean 1.4 days, range 1.2 days-1.9 days.
Total assets$374.4m$355.9m$339.6m$330.5m$334.7m$355m$356.6m
Chart

Reference: annolyse.ai/companies/rad

Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.

Filing-only history charts

These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.

Revenue

Reported revenue across covered periods.

Loading chart...

Revenue growth

Like-period revenue growth where comparable.

Loading chart...
  • FY24 RAD FY: Outside range high revenue growth. 15.4%; 3-period range 3.9% to 14.2%. Revenue growth: 15.4%, above normal range; 3-period mean 9.6%, range 3.9%-14.2%.
  • FY25 RAD FY: Outside range low revenue growth. 3.9%; 3-period range 10.8% to 15.4%. Revenue growth: 3.9%, below normal range; 3-period mean 13.5%, range 10.8%-15.4%.

EBITDA-equivalent

Company-specific earnings measure where disclosed.

Loading chart...

EBITDA margin

EBITDA-equivalent margin where revenue and earnings are source-backed.

Loading chart...
  • FY23 RAD FY: Outside range low ebitda margin. 9.7%; 3-period range 12.4% to 13.7%. EBITDA margin: 9.7%, below normal range; 3-period mean 13.2%, range 12.4%-13.7%.
  • FY26 RAD FY: Outside range high ebitda margin. 13.7%; 3-period range 9.7% to 13.4%. EBITDA margin: 13.7%, above normal range; 3-period mean 11.8%, range 9.7%-13.4%.

NPAT

Statutory profit after tax.

Loading chart...

Operating cash flow

Cash generated from operations.

Loading chart...

More financial metrics

Additional filing-backed metrics for this company. Each point links to the relevant published briefing.

OCF / EBITDA

Cash conversion against earnings.

Loading chart...
  • FY23 RAD FY: Outside range low ocf / ebitda cash conversion. 28.4%; 3-period range 67.4% to 91.8%. OCF / EBITDA cash conversion: 28.4%, below normal range; 3-period mean 81.5%, range 67.4%-91.8%.
  • FY26 RAD FY: Outside range high ocf / ebitda cash conversion. 91.8%; 3-period range 28.4% to 85.5%. OCF / EBITDA cash conversion: 91.8%, above normal range; 3-period mean 60.4%, range 28.4%-85.5%.

FCF pre-lease

Operating cash flow less capex before leases.

Loading chart...

ROE

Return on equity.

Loading chart...
  • FY24 RAD FY: Outside range low roe. -13.2%; 3-period range -2.9% to 12.4%. ROE: -13.2%, below normal range; 3-period mean 6.7%, range -2.9%-12.4%.
  • FY26 RAD FY: Outside range high roe. 12.4%; 3-period range -13.2% to 10.6%. ROE: 12.4%, above normal range; 3-period mean -1.8%, range -13.2%-10.6%.

Net debt

Borrowings less cash; negative values indicate net cash.

Loading chart...

Net debt / EBITDA

Leverage ratio, suppressed where earnings are not meaningful.

Loading chart...
  • FY23 RAD FY: Outside range high net debt / ebitda. 7x; 3-period range 2.51x to 3.5x. Net debt / EBITDA: 7.00x, above normal range; 3-period mean 2.97x, range 2.51x-3.50x.
  • FY26 RAD FY: Outside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x.

DPS

Dividend per share declared for the period.

Loading chart...

Payout ratio

Dividend payout against statutory NPAT.

Loading chart...

Debtor days

Receivables days where the working-capital inputs are source-backed.

Loading chart...
  • FY23 RAD FY: Outside range high debtor days. 33d; 3-period range 21d to 26d. Debtor days: 32.6 days, above normal range; 3-period mean 23.6 days, range 21.2 days-25.6 days.
  • FY26 RAD FY: Outside range low debtor days. 21d; 3-period range 24d to 33d. Debtor days: 21.2 days, below normal range; 3-period mean 27.4 days, range 24.0 days-32.6 days.

Inventory days

Inventory days where the working-capital inputs are source-backed.

Loading chart...
  • FY23 RAD FY: Outside range high inventory days. 2d; 3-period range 1d to 1d. Inventory days: 1.9 days, above normal range; 3-period mean 1.2 days, range 1.1 days-1.2 days.
  • FY26 RAD FY: Outside range low inventory days. 1d; 3-period range 1d to 2d. Inventory days: 1.1 days, below normal range; 3-period mean 1.4 days, range 1.2 days-1.9 days.

Operating working-capital movement

Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.

Loading chart...

The setup & the reality

HY26 → FY26 Follow-through

The latest result is checked against what the prior briefing said to watch.

Historical setup

What HY26 said to watch

Previous analysisHY26Result releasedAnnolyse analysis published

From PBT up 204% on 19% revenue growth as cash conversion lifted to 89%

No quantified FY26 target is provided. Shape context shows HY25 represented only 48% of FY25 revenue and 28% of FY25 NPAT, so the historical pattern is second-half weighted. On that pattern alone, HY26 NPAT of $6.3m already sits close to the full FY25 NPAT of $7.0m, which sets a high bar for second-half delivery before the comparison can be considered conservative.

The release leans on Underlying EBITDA and EBITDAR-per-bed disclosures, with annualised EBITDAR per bed of $29.9k, but does not separate same-store growth from acquired or reconfigured beds. That gap matters because the durability of the operating leverage thesis depends on which mix is driving it.

Open questions

Open questions from HY26

  • What drove the effective tax rate down to 22.3% from 28.6%, and is the lower rate structural or one-off?
  • How much of the EBITDA uplift is same-store versus acquired or reconfigured beds, and what is the same-store occupancy trend?
  • Given HY25 was only 28% of FY25 NPAT, is the historical second-half skew expected to repeat, or has the earnings shape now flattened?
  • What is the target net debt to EBITDA range, and how does the capital-light growth strategy change future capex intensity above the current 3.7% of revenue?
  • Why does the underlying EBITDA bridge still flag non-recurring items, and what residual adjustments sit between underlying and statutory earnings?

This briefing cannot assess occupancy, bed-level pricing, or wage and government-funding assumptions underpinning the EBITDAR-per-bed disclosure.

Latest result sources

Primary issuer documents used for the FY26 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.

Current period

FY26 Investor Presentation

FY26 / results presentation

RAD FY26 Audited Financial Statements

FY26 / financial report

RAD FY26 Media Release

FY26 / media release

RAD FY26 NZX Results Announcement

FY26 / results announcement

Prior comparable period

Radius Care Annual Report 2025

FY25 / financial report

Interim context

RAD 1H26 Interim Report

HY26 / financial report

RAD 1H26 Investor Presentation

HY26 / results presentation

RAD 1H26 Media Release

HY26 / media release

RAD 1H26 NZX Results Announcement

HY26 / results announcement

Release context

RAD Upgraded Outlook and 2025 ASM Materials

HY26 / commentary

Peer context

Aged care comparison set

These companies share the same curated sub-sector label. Their reporting definitions can still differ, so compare the underlying measures before ranking them.

PHL · FY26

Promisia Healthcare

5 published result briefings

Compare RAD, PHL →Healthcare result archiveNZX healthcare comparison

Archive

Briefing archive

The full chronological archive contains every published result briefing.

FY26 · Released 13 May 2026

PBT up 36.2% and cash conversion at 91.8% as capex more than doubled

Underlying earnings ran above the historical baseline, but H2 NPAT roughly halved versus H1 as growth-strategy capex stepped up to NZ$16.1m.

Read briefing

HY26 · Released 19 November 2025

PBT up 204% on 19% revenue growth as cash conversion lifted to 89%

A lower effective tax rate flattered NPAT, but EBITDA +41% and leverage cut to 4.3x point to genuine operating gains.

Read briefing

FY25 · Released 21 May 2025

PBT rose 191.7% to $10.5m as margins and cash conversion stepped up

Margin and cash-conversion gains look durable, but a prior-year tax distortion exaggerates the NPAT swing from a $8.5m loss to a $7.0m profit.

Read briefing

HY25 · Released 25 November 2024

PBT up 75% but reported EBITDA fell 8.1% on a care home sale

Net debt cut 25% and cash conversion improved, but a 94.2% payout sits against a $0.07m cash balance and a higher tax rate.

Read briefing

FY24 · Released 29 May 2024

EBITDA up 47% but NPAT loss widened on tax distortion

Operating earnings and leverage improved sharply, but a 335.8% effective tax rate turned PBT of $3.6m into an $8.5m net loss.

Read briefing

HY24 · Released 27 November 2023

Asset sale puts Radius Residential Care's debt headroom in focus

The NZ$19m disclosed value from the asset sale is relevant to debt headroom, while borrowings and gearing remain the direct evidence.

Read briefing
Open all 7 result briefings

Related insights

Compare this company

The latest RAD metrics also appear in these cross-company comparisons.

Insight

Cash conversion quality

This result converted 91.8% of EBITDA to operating cash flow.

Open insight

Insight

Dividend coverage and payout pressure

Company-disclosed payout ratio is 49.0% on an AFFO basis, with NPAT payout at 66.1%.

Open insight

Insight

Leverage and balance-sheet risk

Net debt / EBITDA is 2.51x for this result.

Open insight

Insight

Revenue growth context

Revenue growth was 14.2% for this reporting period.

Open insight

Get notified when RAD publishes

Get the next Radius Residential Care result briefing and five-year history updates by email.